Innovative hypoglycemic drugs generally need to undergo carcinogenicity testing and evaluation during market application to identify the potential carcinogenic efficacy and risks of the drug. This article takes sodium glucose cotransporter protein (SGLTs) inhibitors, a new type of hypoglycemic drugs that do not depend on insulin levels, as the focus of attention for the treatment of diabetes drugs, as an example. Through the drug information disclosed by the National Drug Administration (NMPA), the U.S. Food and Drug Administration (FDA) and other drug regulatory agencies, this article reviews and combs the carcinogenicity test information of SGLTs drugs that have been marketed at home and abroad, and analyzes and elaborates it, with a view to enhancing the understanding of the carcinogenicity of these drugs and providing reference for the development and evaluation of clinical trials of new drugs.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |